Get to know our clinical trials

Trial of bimekizumab in subjects with moderate to severe hidradenitis suppurativa.

THE PURPOSE OF THIS OPEN-LABEL EXTENSION STUDY IS TO HELP US LEARN HOW SAFE AND EFFECTIVE A NEW DRUG CALLED BIMEKIZUMAB IS IN THE LONG-TERM TREATMENT OF HIDRADENITIS SUPPURATIVA.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE 3, OPEN-LABEL, PARALLEL-GROUP, MULTICENTER, EXTENSION STUDY OF A PREVIOUS STUDY TO EVALUATE LONG-TERM TREATMENT WITH BIMEKIZUMAB IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA. IMMUNOTHERAPY
  • Code EudraCT: 2020-004179-42
  • Protocol number: HS0005
  • Promoter: UCB Biopharma SRL
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.